353282-88-9

Usage

Uses

Used in Pharmaceutical Processes:
1-(4-bromo-2-fluorophenyl)ethanol is used as an intermediate in the synthesis of pharmaceutical compounds due to its unique structure and reactivity, which allows for the creation of more complex organic molecules with potential medicinal properties.
Used in Chemical Manufacturing:
In the chemical manufacturing industry, 1-(4-bromo-2-fluorophenyl)ethanol serves as a building block for the production of other organic compounds, contributing to the development of novel materials and substances with diverse applications.
Used in Material Science:
1-(4-bromo-2-fluorophenyl)ethanol is also utilized in material science as a component in the development of new materials, taking advantage of its specific chemical characteristics to enhance or create materials with improved properties for various applications.
It is crucial to handle 1-(4-bromo-2-fluorophenyl)ethanol with care, as it may present health and safety risks if not properly managed. Its potential applications across different industries highlight the importance of continued research and development to ensure its safe and effective use.

Upstream product

• 676-58-4 methylmagnesium chloride 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 74-88-4 methyl iodide 
• 917-64-6 methyl magnesium iodide 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 625446-22-2 4-bromo-2-fluoroacetophenone 
• 1007583-31-4 2-{[4-(4-bromo-2-fluorophenyl)-1,3-thiazol-2-yl]amino}-2-methylpropan-1-ol 
• 1007583-30-3 2-bromo-4-(4-bromo-2-fluorophenyl)-1,3-thiazole 
• 1007583-29-0 1-(4-bromo-2-fluorophenyl)-2-thiocyanato-1-ethanone 
• 869569-77-7 1-(4-bromo-2-fluorophenyl)-2-bromo-1-ethanone 
• 1426049-95-7 9-(1-(4-bromo-2-fluorophenyl)ethyl)-4-cyclopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 
• 1426049-94-6 4-bromo-1-(1-bromoethyl)-2-fluorobenzene 
• 1426049-93-5 4-cyclopropyl-9-(1-(3-fluoro-4'-methoxy-[1,1'-biphenyl]-4-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one 
• 1142189-49-8 6-bromo-2,3-dimethyl-1H-indazole 
• 1300582-62-0 2,3-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole 
• 1300586-47-3 2-(1-(4-amino-3-(2,3-dimethyl-2H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1300586-44-0 2-(1-(4-amino-3-(1,3-dimethyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1300585-36-7 2-(1-(4-amino-3-(3-methyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1300585-12-9 2-(1-(4-amino-3-(3-methyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 

Relevant academic research and scientific papers

Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mG

This work describes the discovery and characterization of novel 6-(1H-pyrazolo[4,3-b]pyridin-3-yl)amino-benzo[d]isothiazole-3-carboxamides as mGlu4 PAMs. This scaffold provides improved metabolic clearance and CYP1A2 profiles compared to previo

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

Modulators of methyl modifying enzymes, compositions and uses thereof

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein

NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES

The present invention provides, inter alia, compounds of formula ΙΑ,ΙΙΑ and III as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

NOVEL KINASE MODULATORS

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES

The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Oxazolidone derivatives as PR modulators

Compounds of the following structure are described: wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

7-Fluoroindazoles as potent and selective inhibitors of factor Xa

We have developed a novel series of potent and selective factor Xa inhibitors that employ a key 7-fluoroindazolyl moiety. The 7-fluoro group on the indazole scaffold replaces the carbonyl group of an amide that is found in previously reported factor Xa inhibitors. The structure of a factor Xa cocrystal containing 7-fluoroindazole 51a showed the 7-fluoro atom hydrogen-bonding with the N-H of Gly216 (2.9 ?) in the peptide backbone. Thus, the 7-fluoroindazolyl moiety not only occupied the same space as the carbonyl group of an amide found in prior factor Xa inhibitors but also maintained a hydrogen bond interaction with the protein's β-sheet domain. The structure-activity relationship for this series was consistent with this finding, as the factor Xa inhibitory potencies were about 60-fold greater (ΔΔG ≈ 2.4 kcal/mol) for the 7-fluoroindazoles 25a and 25c versus the corresponding indazoles 25b and 25d. Highly convergent synthesis of these factor Xa inhibitors is also described.